Streetbeat News

Price Targets

AAPL

Rosenblatt analyst Barton Crockett maintains a Buy rating on Apple and raises the price target from $261 to $262.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:32 am

ZYME

HC Wainwright & Co. has reiterated a Neutral rating on Zymeworks (NASDAQ:ZYME) and maintained a $12 price target.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:32 am

GDYN

Needham analyst Mayank Tandon maintains a Buy rating on Grid Dynamics Holdings (NASDAQ:GDYN) and raises the price target from $17 to $20.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:30 am

INTC

Rosenblatt analyst Hans Mosesmann maintains a Sell rating on Intel (NASDAQ:INTC) but raises the price target from $17 to $20.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:30 am

IRTC

Baird analyst Mike Polark maintains an Outperform rating on iRhythm Technologies but lowers the price target from $100 to $79.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:28 am

ONTO

Needham analyst Charles Shi maintains a Buy rating on Onto Innovation (NYSE:ONTO) but lowers the price target from $245 to $230.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:28 am

ZYME

Wells Fargo has downgraded Zymeworks from Overweight to Equal-Weight, maintaining the price target at $12.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:25 am

SYRS

HC Wainwright & Co. has reiterated its Buy rating for Syros Pharmaceuticals, maintaining a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:22 am

IQV

Baird analyst Eric Coldwell has maintained a Neutral rating on IQVIA Holdings (NYSE:IQV) while lowering the price target from $256 to $223.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:21 am

INSM

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Insmed (NASDAQ:INSM) and maintained a price target of $90.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:20 am